Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Approves Pain Drug Exparel

By Pharmaceutical Processing | November 1, 2011

PARSIPPANY, N.J. (AP) — Pacira Pharmaceuticals Inc. said Monday that the Food and Drug Administration approved its drug Exparel, which is intended to treat pain following surgery.

The company said it plans to start marketing the drug to hospitals in January, focusing at first on abdominal soft tissue surgeries. Exparel is a long-acting drug that is designed to treat pain for up to three days after surgery. It does not contain opioids. Pacira said it has hired 63 sales representatives, and they will ultimately market the drug for use after abdominal surgeries, plastic surgeries like breast augmentations and abdominoplasties, and balloon-pump replacements.

Pacira also reported its third-quarter results. The company said it lost $9.5 million, or 55 cents per share. A year ago it took a bigger loss of $7.9 million, or $13.77 per share. Its revenue declined to $4 million from $4.5 million.

Analysts expected the company to report a loss of 54 cents per share and $4 million in revenue, according to FactSet.

The company said its selling, general and administrative costs grew to $5 million from $1.7 million. Pacira had about 17.2 million shares on the market in the third quarter of 2011, compared to 574,000 a year earlier.

Shares of Pacira slipped 40 cents, or 4 percent, to $9.78 in Monday trading.

 

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE